Physician

Ramamohana R. Kancherla, M.D.

According to 2025 Medicare claims, Ramamohana Kancherla, M.D. (NPI: 1205904828) practices hematology/oncology in the Kiryas Joel-Poughkeepsie-Newburgh, NY market, with the plurality of this provider's patient population coming from Dutchess, NY. This provider's primary affiliated billing organization is NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (NPI: 1396794574; TIN: 112419534) and primary practice location at 12601-5401. Kancherla is affiliated with the ilumed, LLC (ACO ID: D0005), Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171), and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Kancherla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 907 traditional Medicare patients, billed 192,776 HCPCS/CPT codes, and received $3,282,826 in Medicare payments. The top billing code was 82728 (Ferritin (blood protein) level). Part D data shows 877 prescription claims across 178 beneficiaries totaling $4,655,127 in drug costs, led by Pomalyst (Pomalidomide). 2017 DME data shows 27 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $2,534,431 to $3,282,826. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,254,074 to $4,655,127. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,236	265,050	$2,534,431
2016	869	272,364	$2,581,000
2017	827	168,748	$1,759,612
2018	1,055	212,585	$2,440,748
2019	1,249	269,681	$2,894,236
2020	1,048	323,962	$4,529,961
2021	1,208	328,368	$4,894,497
2022	1,253	303,958	$4,576,515
2023	1,082	273,926	$3,690,441
2024	907	192,776	$3,282,826

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	209	860	$1,254,074
2016	169	656	$1,313,103
2017	171	846	$1,898,261
2018	194	886	$2,396,752
2019	223	911	$2,426,148
2020	161	515	$854,210
2021	121	397	$867,556
2022	114	392	$970,772
2023	117	338	$754,879
2024	178	877	$4,655,127

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	27	$2,293
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
82728	Ferritin (blood protein) level	353	592	$13
80053	Blood test, comprehensive group of blood chemicals	557	1,444	$10
36415	Insertion of needle into vein for collection of blood sample	373	818	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	495	1,946	$8
83615	Lactate dehydrogenase (enzyme) level	500	1,228	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	27	756	$607,311
Revlimid	Lenalidomide	25	700	$457,121
Calquence	Acalabrutinib Maleate	28	840	$409,709
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	52	1,456	$320,069
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	20	560	$254,917

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Ramamohana R. Kancherla, M.D.?

Tedicare shows public-source Medicare data for Ramamohana R. Kancherla, M.D. (NPI 1205904828), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ramamohana R. Kancherla, M.D. have ACO affiliation data?

Ramamohana R. Kancherla, M.D. is shown with ACO affiliation data for ilumed, LLC (REACH, ACO ID D0005), Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171), and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Ramamohana R. Kancherla, M.D.?

Ramamohana R. Kancherla, M.D. is linked to NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (billing NPI 1396794574) in the available physician profile data.

Does Ramamohana R. Kancherla, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.